Tubulysins will be studied in combination with the companies drug delivery system.
Insert Therapeutics and R&D-Biopharmaceuticals will develop and commercialize conjugates of the anticancer compound tubulysin with Insert’s drug delivery system, Cyclosert™. Tubulysins are naturally occurring cytotoxins that prevent cell growth and division by destabilizing microtubules.
R&D will supply Insert with tubulysin technology and material. The two companies will work jointly on the synthesis of the conjugate, after which, Insert will perform the preclinical testing.
The agreement includes an upfront fee to R&D, funding from Insert for R&D’s research, milestone payments on clinical development and approvals, and royalties on product sales. It also provides a research license and an option for an exclusive license to develop and commercialize tubulysin-polymer conjugates.